94 results about "Microsome" patented technology

The preparation and use of nucleic acid fragments encoding fatty acid desaturase enzymes are described. The invention permits alteration of plant lipid composition. Chimeric genes incorporating such nucleic acid fragments with suitable regulatory sequences may be used to create transgenic plants with altered levels of unsaturated fatty acids.

The invention provides compositions and methods for treating hyperlipidemia by administering a Microsomal Triglyceride Transfer Protein (MTP) inhibitor in combination with a Liver Fatty Acid-Binding Protein (L-FABP) inhibitor, methods of preventing the development of hepatic steatosis, methods of identifying an agent useful for treating hyperlipidemia, and methods of screening for inhibitors of MTP and L-FABP activity. Also provided are pharmaceutical compositions comprising a MTP inhibitor and a L-FABP inhibitor.

The invention relates to a detection method for simultaneously determining the metabolic products of seven CYP450 enzyme probe substrate in human liver microsomes, and belongs to the technical field of biological detection. The detection method comprises the following steps: performing incubation on specificity probe substrates of CYP450 enzyme and the human liver microsomes for different periods of reaction time to generate corresponding metabolic products, using Zaltoprofen as an interior label, adopting a high performance liquid chromatography-tandem mass spectrometry after protein precipitation pretreatment, and thus simultaneously detecting the concentrations of the metabolic products of seven probe substrates. The method disclosed by the invention is high in specificity, high in sensitivity and simple and convenient in operation, and has already successfully been applied to the research of baicalin on CYP450 enzyme inhibiting action of the human liver microsomes.

Antisense compounds, compositions and methods are provided for modulating the expression of microsomal triglyceride transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding microsomal triglyceride transfer protein. Methods of using these compounds for modulation of microsomal triglyceride transfer protein expression and for treatment of diseases associated with expression of microsomal triglyceride transfer protein are provided.

Isolated metabolites of the cyclosporine analog ISA247 are disclosed, including in vitro methods for their preparation. The metabolites comprise a chemical modification of ISA247, wherein the modification is at least one reaction selected from the group consisting of hydroxylation, N-demethylation, diol formation, epoxide formation, and intramolecular cyclization phosphorylation, sulfation, glucuronide formation and glycosylation. Methods of preparation include semi-synthetic methods, wherein metabolites of ISA247 are produced from the microsomal extracts of animal liver cells, or from cultures using microorganisms, and completely synthetic methods, such as chemically modifying the parent compound or isolated metabolites using organic synthetic methods.

This invention relates to compounds of formula I

their use as inhibitors of the microsomal prostaglandin E₂ synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R¹, R², R³, R⁴, R⁶, R⁷, R⁹, R^a, R^b have meanings given in the description.

A method for the separation of benzoporphyrin derivative mono and diacid (BPD-MA, BPD-DA) enantiomers by Laser-Induced Fluorescence Capillary Electrophoresis has been developed. The limits of detection are 2.06x10-6 M, and the relative standard deviation for the separation was 2.90% to 4.64%. The BPD enantiomers can be quantitatively determined in the range of 10-2 to 10-5 mg mL-1. In comparison with HPLC, CE has better resolution and efficiency. This separation method was successfully applied to the BPD enantiomers obtained from a matrix of bovine serum and from liposomally formulated material as well as from studies with rat, dog and human microsomes.

The invention provides an antiviral compound preparation for fish. The compound preparation composition comprises microparticles containing macrolide anthelmintic, as well as two or more than two of bithionol, praziquantel, diflubenzuron, triflumuron, pyriproxyfen, sulfur powder, salicylanilide, organic phosphorus, benzimidazole, pyrethroid, triazine, tetramisole anthelmintic, sulfonamides, anticoccidial drugs and Chinese herbal medicine anthelmintic, wherein the microparticles containing macrolide anthelmintic are microspheres or microcapsules composed of biodegradable or non-biodegradable carrier materials and macrolide anthelmintic, and the content of the macrolide anthelmintic in the microparticles is 0.1-50%. The compound preparation provided by the invention can not only expand the insecticidal spectrum, but also effectively improve the anthelmintic activity and reduce toxicity so as to ensure safer use.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

Aromatase inhibitors (AIs) are disclosed which are useful in the treatment and prevention of post-menopausal breast cancer. New AIs derived from natural products are disclosed that are evaluated for clinical utility for treating post-menopausal breast cancer and may also act as chemopreventive agents for preventing breast cancer. Several pure compounds demonstrated AI activity using a noncellular, enzyme-based microsomal and a cell-based aromatase assay. Correlations are made between structural classes with levels of aromatase inhibition. The disclosure may be utilized to direct synthetic modification of natural product scaffolds to enhance aromatase inhibition or to standardize botanical dietary supplements for increased aromatase inhibition activity.

A method for determining P450 content in biological tag ¿C earthworm body includes soaking earthworm living body in glycerin then moving it into salt solution for breaking it to be pieces, moving broken matter into homogenizing solution for homogenizing of 30 ¿C 50 second at 6000 ¿C 8000 rpm, then centrifugalizing homogenized matter for 20 ¿C 30 min at 12000 ¿C 15000 g under 3 ¿C 5 Deg C.; removing off supernatant then centrifugalizing for 90 ¿C 120 min at 120000 ¿C 150000g, discarding supernatant and putting particles in ice water, removing off red matter; dissolving particle in buffer solution and taking out 1 ¿C 2 mI for detecting protein content as the rest for being used to determine P450 content .

Provided herein is a novel and useful method for evaluating the ability of compounds or agents to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase to produce their respective prostaglandin products.

The invention is directed in part to methods for treating and/or controlling hepatitis C in a patient. The methods are directed in part to combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and at least one other active agent.

The invention provides a method for obtaining a haemonchus contortus (H.contortus) microsomal aminopeptidase gene which comprises the steps of total RNA extraction, H11 cDNA sequence clone, homology comparison and amino acid sequence analysis of H11 cDNA sequence as well as H11 genome sequence clone and structural analysis. By referring to the H11 gene cDNA sequence, the method can conveniently, completely and accurately obtain H11 genome sequence, can analyze the H11 mRNA transcription characteristic by analyzing the H11 genome sequence, and provides reliable background material and data for developing H.contortus vaccines. The haemonchus contortus (H.contortus) microsomal aminopeptidase gene that is provided by the invention can be applied to the subunit vaccine preparation that uses recombinant proteins.

Disclosed is a method in which DNA sequences derived from microsome-associated mRNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification. Another embodiment of the invention uses information on the presence or absence of carefully chosen target subsequences in a single sequence clone together with DNA sequence databases to determine the clone sequence. Computer implemented methods are provided to analyze the experimental results and to determine the sample sequences in question and to carefully choose target subsequences in order that experiments yield a maximum amount of information